// App-Quantinova.ai

: TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Researchers

Presenter

  • Mithun V. Shah

Principal Investigators

  • Elizabeth Ngoc Hoa Tran

  • Kirsty M Sharplin

  • Rakchha Chhetri

  • Anmol Baranwal

  • Monika M Kutyna

  • Paul Wang

  • Dariusz Ladon

  • Aref Al-Kali

  • Hassan B. Alkhateeb

  • David M Ross

  • David T Yeung

  • Naranie Shanmuganathan

  • Mark R. Litzow

  • Abhishek A. Mangaonkar

  • William J. Hogan

  • Naseema Gangat

  • Mrinal M.M. Patnaik

  • Begna Kebede

  • Sharad Kumar

  • Deepak Singhal

  • Anna L. Brown

  • Hamish S Scott

  • Daniel Thomas

  • Chung Hoow Kok

  • Ayalew Tefferi

  • Devendra Hiwase

Medical Centers

  • Division of Hematology, Mayo Clinic, ROCHESTER, MN

  • Department of Haematology, Royal Adelaide Hospital, Adelaide, Australia

  • Genetic and Molecular Pathology, SA Pathology, Adelaide, Australia

  • Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

  • ACRF Cancer Genomic Facility, Adelaide, Australia

  • Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia

  • THE UNIVERSITY OF ADELAIDE, Adelaide, Australia

  • Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tumor protein p53

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved